• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Squamous Cell Carcinoma In Situ

Article

Eccentric and irregular pigmentation prompted a biopsy in this elderly woman with a history of basal cell carcinoma and melanoma. The surprising diagnosis was a heavily pigmented squamous cell carcinoma in situ.

An 88-year-old woman presented for a periodic total body skin exam. Her history included basal cell carcinoma and melanoma.

Key point: During the exam, an irregularly pigmented lesion was noted on the upper right arm. The lesion was non-tender and non-pruritic. The differential diagnosis primarily revolved around dysplastic nevus and melanoma. However, a biopsy showed heavily pigmented squamous cell carcinoma in situ.

Treatment: The lesion was completely excised.

Note: The actual diagnosis was surprising. Nonetheless, eccentric and irregular pigmentation in a skin lesion should prompt consideration for a biopsy.

 

Related Content
Lebrikizumab Demonstrates Sustained Disease Control in Atopic Dermatitis Up to 3 Years / image credit - Lilly logo: ©Michael Vi/stock.adobe.com

Lebrikizumab Demonstrates Sustained Disease Control in Atopic Dermatitis Up to 3 Years

Grace Halsey
September 25th 2024
Article

Among adolescents and adults with moderate-to-severe AD, more than 80% achieved sustained disease control, the majority not requiring topical or systemic rescue medication.

Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types / Image credit: ©InfiniteStudio/AdobeStock

Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types

Sydney Jennings
September 25th 2024
Article

Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.

FDA Accepts NDA for Delgocitinib Cream, Developed Specifically to Treat Chronic Hand Eczema / image credit atopic dermatitis: ©Ольга Тернавская/stock.adobe.com

FDA Accepts NDA for Delgocitinib Cream, Developed Specifically to Treat Chronic Hand Eczema

Grace Halsey
September 24th 2024
Article

Delgocitinib specifically inhibits activation of JAK-STAT signaling in chronic hand eczema and would be an option for people unable to use topical corticosteroids.

FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose

Sydney Jennings
September 24th 2024
Article

Your daily dose of the clinical news you may have missed.

Real-World Study Supports Use of DermaSensor in Primary Care to Differentiate Cancerous and Benign Lesions Image credit - DermaSensor logo: ©DermaSensor

Real-World Study Supports Use of DermaSensor in Primary Care to Differentiate Cancerous and Benign Lesions

Grace Halsey
September 23rd 2024
Article

The AI-based point-of-care device outperformed clinician standard of care for sensitivity (90% vs 40%) and had a negative predictive value of 98.9%

Tralokinumab for Treatment of AD in Special Populations: Daily Dose / image credit: ©New Africa/AdobeStock

Tralokinumab for Treatment of AD in Special Populations: Daily Dose

Sydney Jennings
September 20th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.